NMS-03305293

DRUG4 trials

Sponsors

Nerviano Medical Sciences

Conditions

Advanced/Metastatic Solid TumorsDiffuse GliomaGlioblastomaOvarian CancerSmall Cell Lung Cancer

Phase 1

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

TerminatedNCT04182516

Nerviano Medical SciencesAdvanced/Metastatic Solid Tumors

Start: 2019-11-25End: 2024-05-16Updated: 2024-09-19

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Active, not recruitingNCT04910022

Nerviano Medical SciencesDiffuse Glioma, Glioblastoma

Start: 2021-12-01End: 2027-09-07Target: 150Updated: 2025-08-19

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

RecruitingNCT06930755

Nerviano Medical SciencesOvarian Cancer

Start: 2026-05-13End: 2027-09-26Target: 24Updated: 2026-05-28

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

RecruitingNCT06931626

Nerviano Medical SciencesSmall Cell Lung Cancer

Start: 2025-08-15End: 2027-02-28Target: 10Updated: 2026-07-24

Related Papers

P27.26.B TUMOR GROWTH RATE IN RECURRENT GLIOBLASTOMA: WHEN TO PLAN THE BASELINE SCAN?

Neuro-Oncology2024-10-01

Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor

Molecular Cancer Therapeutics2023-12-015 citations